Overview
SLN market data
Price History
SLN price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.53 Diluted earnings per share over the trailing twelve months.
- Beta
- 2.48 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $1.06 – $2.63 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $496 · P/B 3.53 · P/S 591.14.
Company News
This $300 Million Biotech May Be Deeply Mispriced: AnalystBenzinga · Jun 24, 2026, 6:25 PM
Cantor Fitzgerald Initiates Coverage On Silence Therapeutics with Overweight RatingBenzinga · Jun 24, 2026, 2:10 PM
Sophia Genetics, Ormat Technologies And Other Big Stocks Moving Lower In Wednesday's Pre-Market SessionBenzinga · Jun 17, 2026, 12:10 PM
Silence Therapeutics Stock Rises On Positive Blood Cancer Drug DataBenzinga · Jun 12, 2026, 2:50 PM
Silence Therapeutics shares are trading higher. The company presented follow-up and quality-of-life data from the Phase 1 SANRECO study evaluating divesiran in polycythemia vera at the EHA 2026 Annual Congress.Benzinga · Jun 11, 2026, 5:22 PM
Silence Therapeutics Presents Follow-Up, Quality-Of-Life Data From Phase 1 SANRECO Study Evaluating Divesiran In 21 Phlebotomy-Dependent Patients With Polycythemia Vera At EHA 2026 Annual Congress.Benzinga · Jun 11, 2026, 5:20 PM